Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Profit After Tax (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Profit After Tax for 11 consecutive years, with -$92.4 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax changed N/A to -$92.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$154.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$153.9 million for FY2025, 306.4% down from the prior year.
  • Profit After Tax for Q4 2025 was -$92.4 million at Crescent Biopharma, down from -$24.6 million in the prior quarter.
  • The five-year high for Profit After Tax was -$2.6 million in Q3 2024, with the low at -$92.4 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$17.1 million, with a median of -$13.3 million recorded in 2022.
  • The sharpest move saw Profit After Tax skyrocketed 71.41% in 2024, then crashed 835.01% in 2025.
  • Over 5 years, Profit After Tax stood at -$17.4 million in 2021, then soared by 41.2% to -$10.2 million in 2022, then increased by 11.38% to -$9.1 million in 2023, then surged by 71.02% to -$2.6 million in 2024, then tumbled by 3413.57% to -$92.4 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$92.4 million, -$24.6 million, and -$21.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.